CT-Based Radiomics Analysis to Predict Malignancy in Patients with Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas

被引:39
|
作者
Tobaly, David [1 ]
Santinha, Joao [2 ,3 ]
Sartoris, Riccardo [1 ,4 ]
Dioguardi Burgio, Marco [1 ,4 ]
Matos, Celso [5 ,6 ]
Cros, Jerome [7 ]
Couvelard, Anne [8 ]
Rebours, Vinciane [9 ]
Sauvanet, Alain [10 ]
Ronot, Maxime [1 ,4 ]
Papanikolaou, Nikolaos [11 ]
Vilgrain, Valerie [1 ,4 ]
机构
[1] Hop Beaujon, AP HP Nord, AP HP, Serv Radiol, F-92110 Clichy, France
[2] Champalimaud Fdn, Champalimaud Res, Computat Clin Imaging Grp, Ave Brasilia, P-1400038 Lisbon, Portugal
[3] Univ Lisbon, Inst Super Tecn, Inst Telecomunicacoes, P-1049001 Lisbon, Portugal
[4] Univ Paris, INSERM, U1149, Ctr Rech Inflammat Cri, F-75018 Paris, France
[5] Champalimaud Fdn, Radiol Dept, Ave Brasilia, P-1400038 Lisbon, Portugal
[6] Champalimaud Fdn, Champalimaud Res, Ave Brasilia, P-1400038 Lisbon, Portugal
[7] Hop Beaujon, AP HP Nord, AP HP, Serv Anatomopathol, F-92110 Clichy, France
[8] Hop Bichat Claude Bernard, AP HP Nord, AP HP, Serv Anatomopathol, F-75018 Paris, France
[9] Hop Beaujon, AP HP Nord, AP HP, Serv Pancreatol, F-92110 Clichy, France
[10] Hop Beaujon, AP HP Nord, AP HP, Serv Chirurg HPB, F-92110 Clichy, France
[11] Champalimaud Fdn, Champalimaud Res, Computat Clin Imaging Grp, P-1400038 Lisbon, Portugal
关键词
risk stratification; quantitative imaging; texture; malignant transformation; radiomics; pancreatic cyst; INTERNATIONAL CONSENSUS GUIDELINES; PHASE HELICAL CT; IMAGING FEATURES; MANAGEMENT; CYSTS; PERFORMANCE; PREVALENCE; DIAGNOSIS; SYSTEM;
D O I
10.3390/cancers12113089
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The management of intraductal papillary mucinous neoplasms of the pancreas (IPMN) remains controversial due to the relatively high rate of unnecessary surgery for low grade dysplasia (LGD) despite the last international recommendations. The aim of our retrospective study was to assess the performance of radiomic analysis on CT in differentiating benign from malignant IPMN. We confirmed in a training cohort (296 patients) and a validation cohort (112 patients) that a total of 85 radiomics features provided valuable additional and independent information for discriminating benign from malignant tumors in the training cohort with an area under the ROC curve (AUC) of 0.84 and an external validation with an AUC of 0.71 with higher performance when implementing clinical variables leading to the indication to surgery. We have demonstrated the capabilities of radiomics models comprising LGD versus high-grade dysplasia (HGD) versus invasive, LGD and HGD, HGD and invasive. To assess the performance of CT-based radiomics analysis in differentiating benign from malignant intraductal papillary mucinous neoplasms of the pancreas (IPMN), preoperative scans of 408 resected patients with IPMN were retrospectively analyzed. IPMNs were classified as benign (low-grade dysplasia, n = 181), or malignant (high grade, n = 128, and invasive, n = 99). Clinicobiological data were reported. Patients were divided into a training cohort (TC) of 296 patients and an external validation cohort (EVC) of 112 patients. After semi-automatic tumor segmentation, PyRadiomics was used to extract radiomics features. A multivariate model was developed using a logistic regression approach. In the training cohort, 85/107 radiomics features were significantly different between patients with benign and malignant IPMNs. Unsupervised clustering analysis revealed four distinct clusters of patients with similar radiomics features patterns with malignancy as the most significant association. The multivariate model differentiated benign from malignant tumors in TC with an area under the ROC curve (AUC) of 0.84, sensitivity (Se) of 0.82, specificity (Spe) of 0.74, and in EVC with an AUC of 0.71, Se of 0.69, Spe of 0.57. This large study confirms the high diagnostic performance of preoperative CT-based radiomics analysis to differentiate between benign from malignant IPMNs.
引用
收藏
页码:1 / 19
页数:19
相关论文
共 50 条
  • [31] 16-slice multidetector CT evaluation of intraductal mucinous papillary neoplasm (IPMN) of the pancreas: Can CT differentiate benign IPMN from malignant IPMN?
    Kawamoto, S
    Horton, KM
    Lawler, LP
    Hruban, RH
    Fishman, EK
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2005, 184 (04) : 97 - 97
  • [32] Clinicopathological Correlates of Activating GNAS Mutations in Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
    Marco Dal Molin
    Hanno Matthaei
    Jian Wu
    Amanda Blackford
    Marija Debeljak
    Neda Rezaee
    Christopher L. Wolfgang
    Giovanni Butturini
    Roberto Salvia
    Claudio Bassi
    Michael G. Goggins
    Kenneth W. Kinzler
    Bert Vogelstein
    James R. Eshleman
    Ralph H. Hruban
    Anirban Maitra
    Annals of Surgical Oncology, 2013, 20 : 3802 - 3808
  • [33] Incidence of synchronous and metachronous extrapancreatic malignant neoplasms in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas
    Hisai, H.
    Tanaka, I.
    Ono, M.
    Yamada, S.
    Miyazaki, E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 228 - 228
  • [34] Does Splenic Vein Thrombosis Predict Invasive Malignancy in Side-Branch Intraductal Papillary Mucinous Neoplasm (IPMN)?
    Sweetser, Seth
    Vege, Santhi Swaroop
    Clain, Jonathan E.
    Topazian, Mark D.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (09): : 2412 - 2413
  • [35] Proteomic assessment of markers for malignancy in the mucus of intraductal papillary mucinous neoplasms of the pancreas (IPMN)
    Corcos, Olivier
    Couvelard, Anne
    Sauvanet, Alain
    Dargere, Delphine
    Maire, Frederique
    Paradis, Valerie
    Hammel, Pascal
    Levy, Philippe
    Ruszmewski, Philippe B.
    Bedossa, Pierre
    GASTROENTEROLOGY, 2008, 134 (04) : A699 - A699
  • [36] Intraductal papillary mucinous neoplasm (IPMN) of the main pancreatic duct
    Cameselle-Garcia, Soledad
    Gonzalez Soler, Juan J.
    Pena-Zemsch, Milagros M.
    Latorre-Diez, Ana
    GALICIA CLINICA, 2018, 79 (03): : 92 - 94
  • [37] Intraductal Papillary Mucinous Neoplasm (IPMN): MiRNA Molecular Profiling of Individuals at High Risk for Malignancy
    Lubezky, N.
    Lowenstein, S.
    Nachmany, I.
    Ben Haim, M.
    Nakache, R.
    Santo, I.
    Inbar, M.
    Halperin, Z.
    Klausner, J.
    Lahat, G. J.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S152 - S152
  • [38] Number of Worrisome Features is Associated With Increasing Risk of Malignancy in Intraductal Papillary Mucinous Neoplasm (IPMN)
    Zelga, P. J.
    Hernandez-Barco, Y.
    Qadan, M.
    Ferrone, C.
    Kambadakone, A.
    Jah, A.
    Warshaw, A. L.
    Lillemoe, K. D.
    Balakrishnan, A.
    Fernandez-del Castillo, C.
    PANCREAS, 2021, 50 (07) : 1111 - 1111
  • [39] Risk Factors for Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas: A Multicentre Case - Control Study
    Capurso, Gabriele
    Boccia, Stefania
    Salvia, Roberto
    Del Chiaro, Marco
    Frulloni, Luca
    Arcidiacono, Paolo Giorgio
    Zerbi, Alessandro
    Manta, Raffaele
    Fabbri, Carlo
    Ventrucci, Maurizio
    Tarantino, Ilaria
    Piciucchi, Matteo
    Carnuccio, Antonella
    Boggi, Ugo
    Leoncini, Emanuele
    Costamagna, Guido
    Delle Fave, Gianfranco
    Pezzilli, Raffaele
    Bassi, Claudio
    Larghi, Alberto
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 (06): : 1003 - 1009
  • [40] Management of intraductal papillary mucinous neoplasm of the pancreas
    Sugiyama, Masanori
    Suzuki, Yutaka
    Abe, Nobutsugu
    Mori, Toshiyuki
    Atomi, Yutaka
    JOURNAL OF GASTROENTEROLOGY, 2008, 43 (03) : 181 - 185